- No details provided in
stipulation and proposed orderof dismissal, approved Friday in federal court in Wilmington, Delaware
- Patents cover drug’s active ingredient, diroximel fumarate, and its use in treating MS, and expire in September 2033: FDA Orange Book
- Biogen has predicted $1 billion peak-sales potential for Vumerity, though Bloomberg Intelligence analyst
Marc Engelsgjerdsaid July 22that reaching that figure “seems a tall order”
Biogen Target Slashed At Guggenheim as Aduhelm ...
Oct. 11, 2021, 3:17 PM
Biogen, Alkermes Settle Patent Suit with Teva on Vumerity Copies